Elutia, Inc. Stock Plummets to New 52-Week Low of $1.17

Elutia, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.17 on September 15, 2025. This significant decline reflects a challenging year for the company, which has seen its stock price plummet by 64.84% over the past year, contrasting sharply with the S&P 500's performance of 17.67% during the same period.
The company's market capitalization stands at approximately USD 80 million, indicating its microcap status. Elutia's financial metrics reveal a loss-making position, with a negative book value and a concerning debt-to-equity ratio of -0.62. The company has struggled with long-term growth, evidenced by a decline in net sales at an annual rate of -15.13% and operating profit decreasing by 24.32% over the last five years.

Recent financial results have also shown weak performance, with operating cash flow hitting a low of USD -32.8 million and a pre-tax profit of USD -7.83 million. As Elutia navigates these financial challenges, its stock performance continues to reflect a difficult market position.